Systemic therapy is often given late due to optimism bias, treatment momentum, and difficulty in end-of-life conversations, leading to increased hospitalizations and ICU admissions. MD Anderson Cancer ...
—Building off of earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer and identify factors ...
A cohort analysis of patients treated with RC for MIBC across the United States was performed using the National Cancer Database. The primary outcome measure was overall survival (OS), defined as the ...
The U.S. Food and Drug Administration (FDA) has approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have specific HER2 ...
Systemic treatment for human epidermal growth factor receptor 2-positive breast cancer includes a range of targeted therapies designed to inhibit HER2 signaling, improve tumor response and limit ...
Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered – chronological age. The study, ...
CEOCFO interviews NanOlogy, LLC CEO David J. Arthur on Solving Toxicity & Bioavailability Problems when Treating ...
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results